The battle against antibiotic resistance in neonatal sepsis is far from over, especially in low- and middle-income countries (LMICs). A recent study presented at the ESCMID annual meeting in Munich highlights the stark reality of treating this deadly infection in newborns in these regions. The BARNARDS II study, a prospective investigation into antibiotic use and outcomes in newborns with sepsis in Pakistan, Nigeria, and Bangladesh, reveals a grim picture.
Neonatal sepsis, a life-threatening condition caused by bacteria or fungi entering the bloodstream, claims an estimated 200,000 newborn lives annually, with over 90% of these deaths occurring in LMICs. The World Health Organization (WHO) recommends ampicillin plus gentamicin as the empiric treatment for neonatal sepsis. However, the BARNARDS II study's findings cast doubt on the effectiveness of this approach in these regions.
Of the 14,259 newborns treated empirically for suspected sepsis, only 40 received the ampicillin-gentamicin combination. When analyzing culture-confirmed cases, it was discovered that this combination would have been effective against only 25% of the cases, due to high levels of resistance to the therapy. This limited coverage against locally prevalent, highly resistant pathogens is a significant concern.
The study's lead author, Kathryn Thomson, emphasizes that the ineffectiveness of ampicillin and gentamicin explains why clinicians opted for alternative two-drug combinations, such as amikacin plus cefotaxime. This adaptation to local resistance patterns is a practical response to the challenges of applying global treatment recommendations in resource-constrained settings.
The study also highlights the limitations of the 'one-size-fits-all' approach for neonatal sepsis treatment guidelines. The WHO's recommendation is based on data from high-income countries, which does not accurately reflect the distribution of pathogens and antimicrobial resistance (AMR) patterns in LMICs. The urgency of treating neonatal sepsis within hours to prevent severe outcomes underscores the need for locally informed treatment strategies.
Co-author Timothy Walsh underscores the importance of tailored empiric treatment strategies, enhanced diagnostics, continued AMR surveillance, and sustainable access to effective antibiotics in improving neonatal sepsis outcomes in LMICs. The study's findings emphasize the need for a more nuanced and context-specific approach to antibiotic treatment in these regions, rather than relying on global guidelines that may not be applicable.
In conclusion, the BARNARDS II study serves as a stark reminder of the complex challenges in combating antibiotic resistance in neonatal sepsis in LMICs. It highlights the need for further research and tailored solutions to address the unique circumstances of these regions, ensuring that newborns receive the best possible care and a chance at survival.
